XMYRCLA Trademark

Trademark Overview

On Thursday, January 12, 2023, a trademark application was filed for XMYRCLA with the United States Patent and Trademark Office. The USPTO has given the XMYRCLA trademark a serial number of 79362731. The federal status of this trademark filing is REGISTERED as of Tuesday, February 13, 2024. This trademark is owned by Merck KGaA. The XMYRCLA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer
xmyrcla

General Information

Serial Number79362731
Word MarkXMYRCLA
Filing DateThursday, January 12, 2023
Status700 - REGISTERED
Status DateTuesday, February 13, 2024
Registration Number7301623
Registration DateTuesday, February 13, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 28, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMerck KGaA
Party Type30 - Original Registrant
Legal Entity Type31 - NOT AVAILABLE
AddressDE
Party NameMerck KGaA
Party Type20 - Owner at Publication
Legal Entity Type31 - NOT AVAILABLE
AddressDE
Party NameMerck KGaA
Party Type10 - Original Applicant
Legal Entity Type31 - NOT AVAILABLE
AddressDE

Trademark Events

Event DateEvent Description
Friday, March 17, 2023ASSIGNED TO EXAMINER
Thursday, February 16, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, February 16, 2023LIMITATION FROM ORIGINAL APPLICATION ENTERED
Tuesday, February 21, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, February 25, 2023APPLICATION FILING RECEIPT MAILED
Friday, March 17, 2023NON-FINAL ACTION WRITTEN
Saturday, March 18, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, May 8, 2023REFUSAL PROCESSED BY MPU
Monday, May 8, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, May 12, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 31, 2023REFUSAL PROCESSED BY IB
Wednesday, October 4, 2023ASSIGNED TO LIE
Wednesday, October 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 4, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, October 14, 2023ASSIGNED TO EXAMINER
Saturday, October 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 8, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 8, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, November 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 13, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, November 28, 2023NOTIFICATION PROCESSED BY IB
Tuesday, November 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, November 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 13, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, May 20, 2024FINAL DISPOSITION NOTICE SENT TO IB
Monday, May 20, 2024FINAL DISPOSITION PROCESSED
Monday, May 13, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, June 11, 2024FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

xmyrcla cancer treatment preparations pharmaceutical